# Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

> **NCT00089128** · PHASE2 · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 16 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00089128
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2018-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089128, "Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00089128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*